Business Insider spoke to Eli Lilly's new president of cardiometabolic health, who shared the company's aggressive incretin ...

LLY, NFLX, and GE lead today's top stock picks, with strong growth drivers but face headwinds from pricing, rivals, and costs ...

Eli Lilly (LLY-2.55%) is working to capture as much of that market as it can, ... As you'll see, that hope is a key theme in Eli Lilly's strategy for the obesity market.

Though Novo Nordisk and Eli Lilly are the giants in the GLP-1 boom, biotech execs say there are many more approaches and uses to be explored. Skip to Main Content Donald Trump ...

Shares of Eli Lilly And Co (NYSE: LLY) were climbing during Friday's trading session. The stock has been under pressure for the past three months, due to macro uncertainties and not ...

The acquisition aligns with Eli Lilly’s broader diversification strategy beyond its core diabetes and obesity treatment portfolio. Verve’s innovative gene-editing technology, which permanently ...

While Eli Lilly has struggled in the past year due to competitive pressures, the statistical winds may finally favor LLY ...

Some of the potential iterations of delivery methods Eli Lilly considered for orforglipron, at Eli Lilly’s headquarters in Indianapolis on March 31. The ultimate form has yet to be finalized.

J.P. Morgan Research estimates that the GLP-1 market will reach $100 billion by 2030, fueled equally by diabetes and obesity. By 2030, there may be 30 million GLP-1 users in the United States, or ...

Eli Lilly and Company (NYSE:LLY), a leading pharmaceutical giant with a market capitalization of $724 billion, has been making waves in the healthcare sector with its groundbreaking treatments for ...